News

Jack Talley, president and chief executive officer of EpiCept, said: “NP-1’s orphan drug designation is another indication of the significant need that exists for new and more effective

Galectin-3 has been shown by researchers at the University of Maastricht, the Netherlands, to play an integral role in the development and progression of heart failure. The company

The year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered in the

Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care settings. Ulimorelin is a small molecule, intravenously-administered

The compnay claims that Maris Plus stent features an exclusive cell design at the stent ends. This allows physicians to place several stents in series without stiffening the

The trial, which is being conducted by the Hoosier Oncology Group, is open for enrollment at the Baylor Sammons Cancer Centre, Dallas, Texas; Indiana University Melvin and Bren

Enzon’s specialty pharmaceutical business includes four marketed products, Oncaspar, Adagen, DepoCyt, and Abelcet, as well as a manufacturing facility in Indianapolis, Indiana. As previously announced, Enzon entered into

With the completion of the design of the self-metering cartridge, a limited production run will be released, which will enable the company to adapt its first cardiovascular test,

The NDA submission follows a pre-NDA meeting with the FDA and the recently announced results from the phase 3 trial of Axiron. The trial demonstrated that after four